Department of Medicine and Center for Genomic and Computational Biology, Duke Cancer Institute, Duke University, Durham, North Carolina 27707, USA.
Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):a034843. doi: 10.1101/cshperspect.a034843.
Non-Hodgkin lymphomas (NHLs) are a diverse group of entities, both clinically and molecularly. Here, we review the evolution of classification schemes in B-cell lymphoma, noting the now standard WHO classification system that is based on immune cell-of-origin and molecular phenotypes. We review how lymphomas arise throughout the B-cell development process as well as the molecular and clinical features of prominent B-cell lymphomas. We provide an overview of the major progress that has occurred over the past decade in terms of our molecular understanding of these diseases. We discuss treatment options available and focus on a number of the diverse research tools that have been employed to improve our understanding of these diseases. We discuss the problem of heterogeneity in lymphomas and anticipate that the near future will bring significant advances that provide a measurable impact on NHL outcomes.
非霍奇金淋巴瘤(NHL)在临床和分子水平上都是一组多样化的实体。在这里,我们回顾了 B 细胞淋巴瘤分类方案的演变,指出了现在基于免疫细胞起源和分子表型的标准世卫组织分类系统。我们回顾了淋巴瘤如何在整个 B 细胞发育过程中产生,以及突出的 B 细胞淋巴瘤的分子和临床特征。我们概述了过去十年中在这些疾病的分子理解方面取得的主要进展。我们讨论了现有的治疗选择,并重点介绍了一些用于提高我们对这些疾病认识的多样化研究工具。我们讨论了淋巴瘤异质性的问题,并预计不久的将来将取得重大进展,对 NHL 结果产生可衡量的影响。